Guggenheim analyst Eddie Hickman raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the shares. The firm expects growth to continue as the GeneDx program drives new diagnoses, the European opportunity crystallizes, and patient retention remains high, the analyst tells investors in a post-Q1 note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Analyst Reiterates Buy on Zevra, Keeps DCF-Based Price Target Unchanged at $24 Amid Robust Miplyffa Performance and Pipeline Optionality
- Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Execution, Debt-Free Balance Sheet Support Upside with Price Target Maintained at $26
- Zevra Therapeutics reports Q1 EPS 60c, consensus 8c
- Zevra Therapeutics Earnings Call Signals Profitable Turn
- Zevra Pharmaceuticals: SDX Monetization, Debt Elimination, and Miplyffa Ramp Support Buy Rating